PLoS medicine
-
Trachoma accounts for 15% of blindness worldwide, affecting the world's poorest communities. How can the disease be controlled?
-
Are short synthetic peptides the key to developing cancer vaccines? And what are the obstacles in the way?
-
The development of enzyme replacement therapy for Gaucher disease was a triumph of translational medicine. What were the key steps in its development? What are the controversies surrounding its use?
-
Nobody should do a new research study, says Clarke, without first systematically reviewing the literature. And journal editors should insist that all research papers are accompanied by an up-to-date systematic review
-
Most analyses of risks to health focus on the total burden of their aggregate effects. The distribution of risk-factor-attributable disease burden, for example by age or exposure level, can inform the selection and targeting of specific interventions and programs, and increase cost-effectiveness. ⋯ Many major global risks are widely spread in a population, rather than restricted to a minority. Population-based strategies that seek to shift the whole distribution of risk factors often have the potential to produce substantial reductions in disease burden.